Endocannabinoid involvement in endometriosis

Dmitrieva et al. ·Pain Impact 4.2

Klarer Nutzen GRADE Sehr niedrig 64 Zitate

StichprobePräklinisch

Dauerunklar

KontrolleCB1-Rezeptor-Antagonisten

EndpunktEndometriose-assoziierte…

Verblindungn.a.

DesignPräklinisch

Kernaussage

CB1-Rezeptor-Agonisten verringerten endometriose-assoziierte Hyperalgesie in einem Rattenmodell; CB1-Antagonisten erhöhten sie.

Zusammenfassung

Präklinische Studie zu Endocannabinoid-System bei Endometriose; Nachweis reduzierter CB1-Rezeptor-Expression und veränderte Anandamid-Spiegel in ektopem Endometrium, Hinweise auf ECS-Dysregulation als pathophysiologischer Faktor

PopulationRatten mit experimenteller Endometriose (Tiermodell), Anzahl nicht im Abstract spezifiziert

InterventionCB1-Cannabinoid-Rezeptor-Agonisten (Substanz und Dosis nicht im Abstract genannt)

KontrolleCB1-Rezeptor-Antagonisten (als Kontroll-Intervention zur Validierung des Wirkmechanismus)

OutcomeCB1-Agonisten reduzierten Endometriose-assoziierte Hyperalgesie, CB1-Antagonisten verstärkten diese (keine quantitativen Daten im Abstract)

Vertrauen in die Evidenz

Sehr niedrig

Niedrigste GRADE-Stufe, die Effektschätzung bleibt unsicher.

Herabgestuft wegen

Indirektheit

Qualitätsprofil

Größe —

Verblindung —

Effektstärke Klarer Nutzen

Zitate / Jahr ★★★★★

Autoren

Dmitrieva N, Nagabukuro H, Resuehr D et al.

DOI 10.1016/j.pain.2010.08.037↗

Design: Präklinisch

Abstract

Endometriosis is a disease common in women that is defined by abnormal extrauteral growths of uterine endometrial tissue and associated with severe pain. Partly because how the abnormal growths become associated with pain is poorly understood, the pain is difficult to alleviate without resorting to hormones or surgery, which often produce intolerable side effects or fail to help. Recent studies in a rat model and women showed that sensory and sympathetic nerve fibers sprout branches to innervate the abnormal growths. This situation, together with knowledge that the endocannabinoid system is involved in uterine function and dysfunction and that exogenous cannabinoids were once used to alleviate endometriosis-associated pain, suggests that the endocannabinoid system is involved in both endometriosis and its associated pain. Herein, using a rat model, we found that CB1 cannabinoid receptors are expressed on both the somata and fibers of both the sensory and sympathetic neurons that innervate endometriosis's abnormal growths. We further found that CB1 receptor agonists decrease, whereas CB1 receptor antagonists increase, endometriosis-associated hyperalgesia. Together these findings suggest that the endocannabinoid system contributes to mechanisms underlying both the peripheral innervation of the abnormal growths and the pain associated with endometriosis, thereby providing a novel approach for the development of badly-needed new treatments.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel